Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
520 Country Club Rd
Eugene, OR 97401- Is this information wrong?
Summary
- Dr. Bo Wang is an oncologist in Eugene, OR. He received his medical degree from Albert Einstein COM. He trained at Icahn Mount Sinai School of Medicine for hematology and oncology. Dr. Wang specializes in head & neck cancer, multiple myeloma, and thoracic cancers. Dr. Wang is principal investigator on numerous lung cancer clinical trials.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2018 - 2021
Tufts Medical CenterResidency, Internal Medicine, 2015 - 2018
Albert Einstein College of MedicineClass of 2015
Certifications & Licensure
OR State Medical License 2021 - 2025
NY State Medical License 2018 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Start of enrollment: 2020 Dec 02
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2022 Oct 12
- Study of Novel Treatment Combinations in Patients With Lung Cancer Start of enrollment: 2023 Mar 16
- Join now to see all
Publications & Presentations
PubMed
- Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.Adeel M Khan, Georgia McCaughan, Xiaoliang Wang, James Roose, Larry D Anderson Jr, Fieke W Hoff, Rahul Banerjee, Bo Wang, Andrew J Cowan, S Vincent Rajkumar, Gurbakhas...> ;Blood Cancer Journal. 2024 Mar 22
- 4 citationsClinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.Qin, Q., Jun, T., Wang, B., Patel, V., Mellgard, G., Zhong, X., Gogerly-Moragoda, M., Parikh, A., Leiter, A., Gallagher, E., Alerasool, P., Garcia, P., Joshi, H., Mbbs...> ;Discover. Oncology. 2022 Aug 12
- 14 citationsBeneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain InjuryBo Wang, Mitchell Kang, Michelle Marchese, Esther Rodriguez, Wei Lu, Xintong Li, Yasuhiro Maeda, Peter C. Dowling> ;Neurotherapeutics. 2016 Apr 1
- Join now to see all
Journal Articles
- Chimeric antigen receptor T-cell therapeutics for multiple myeloma: moving into the spotlight.Bo Wang, Sridevi Rajeeve, Deepu Maddur, The Cancer Journal, 4/1/2021
Press Mentions
EVOKE 02 in NSCLCNovember 15th, 2023
COVID-19: Rates of Hospitalization and Mortality Among Patients with Multiple MyelomaAugust 19th, 2020
Committees
- Committee Member, USON Thoracic Research
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Hospital Affiliations
PeaceHealth Sacred Heart Medical Center at RiverBendSpringfield, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
